MCK vs PMCB · P/E 20, rev $403.43B vs $8.6M cap
McKesson Corporation (MCK) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
McKesson Corporation (MCK) is a medical distribution company listed on NYSE.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported MCK revenue for 2026-03-31 was $403.43B. Net income was $4.76B. Revenue was up 12.4% from 2025-03-31 to 2026-03-31. MCK currently screens at market cap $91.30B and trailing P/E 20.3.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
MCK currently screens at market cap $91.30B and trailing P/E 20.3. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the MCK and PMCB stock pages for the full models.
Not investment advice.